Get the Stockscreener App
4.505
8.03%
0.335
After Hours:
4.50
-0.005
-0.11%
Telomir Pharmaceuticals Inc stock is traded at $4.505, with a volume of 127.39K.
It is up +8.03% in the last 24 hours and down -0.33% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$4.17
Open:
$4.17
24h Volume:
127.39K
Relative Volume:
0.73
Market Cap:
$134.04M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-10.20
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
-2.91%
1M Performance:
-0.33%
6M Performance:
+34.88%
1Y Performance:
+0.00%
1-Day Range:
$4.17
$4.62
1-Week Range:
$4.1401
$5.02
52-Week Range:
$3.11
$20.72
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
4.505 | 134.04M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
TELO Treatment Amazes in Preclinical Trial - MSN
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart
Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart
Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Triple Negative Breast Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs - Barchart
Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight - Barchart
Telomir Pharmaceuticals Announces Breakthrough Results with Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as A Treatment for Avian Influenza (Bird Flu) and Other Viruses - Marketscreener.com
Thumzup Media (NASDAQ: TZUP) Reports 230% Advertiser Growth, Expands National Presence - Barchart
Stocks In Play: NextSource Materials Inc. - Barchart
Telomir touts potential of Telomir-1 in addressing oxidative stress - MSN
Stocks In Play: CGI Inc. - Barchart
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Pancreatic Cancer Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma - Barchart
Pharma company reports potential of 'age-reversal' molecule - The Business Journals
Telomir Pharmaceuticals reports reversal of oxidative stress - MSN
Telomir Pharmaceuticals reports reversal of oxidative stress By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses - ACCESS Newswire
Telomir touts potential of Telomir-1 in addressing oxidative stress (TELO:NASDAQ) - Seeking Alpha
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - ACCESS Newswire
Barclays PLC Purchases 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December - MarketBeat
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week - Yahoo Finance
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Geode Capital Management LLC Has $1.53 Million Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Stocks In Play: Almonty Industries Inc. - Barchart
Telomir Pharmaceuticals reports breakthrough in progeria study By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals confirms lifespan restoration in Progeria preclinical model with Telomir-1 - MSN
Telomir Pharmaceuticals reports breakthrough in progeria study - Investing.com
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) - AccessWire
State Street Corp Acquires 17,967 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Elon Musk Weighs In On Weight-Loss Drug Stocks. Is LLY Or NVO A Better Buy? - Barchart
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 22.9% - MarketBeat
Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World
Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst
Telomir-1 shows promise in copper binding studies - Investing.com
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - Chronicle-Tribune
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance
Telomir Pharmaceuticals appoints new accounting firm - Investing.com India
Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Telomir Pharmaceuticals secures $1 million equity funding - Investing.com
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire
Telomir Pharmaceuticals Secures Premium-Priced Funding After Breakthrough Anti-Aging Drug Results - StockTitan
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):